Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

NCT03344419 · clinicaltrials.gov ↗

PHASE3

Phase

SUSPENDED

Status

150

Enrollment

OTHER

Sponsor class

Stopped Funding

Conditions

Cocaine Use Disorder

Interventions

DRUG: CI-581a
DRUG: CI-581b
BEHAVIORAL: Motivational Enhancement Therapy (MET)
BEHAVIORAL: Mindfulness Based Relapse Prevention

Sponsor

New York State Psychiatric Institute

Collaborators

[object Object]